FWA
BHVN

FSC Wealth Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

FSC Wealth Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,300
Closed -$499K – 224
2022
Q3 		$499K Hold
3,300
– – 4.81% 4
2022
Q2 		$481K Hold
3,300
– – 4.26% 4
2022
Q1 		$391K Buy
3,300
+300
+10% +$37.4K 0.37% 18
2021
Q4 		$413K Buy
+3,000
New +$381K 0.28% 26

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

FSC Wealth Advisors's BHVN Position: Q4 2022 in Review

FSC Wealth Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 3,300 shares — an estimated $499K sold.

FSC Wealth Advisors first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $499K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • FSC Wealth Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • FSC Wealth Advisors sold 3,300 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $499K.
  • FSC Wealth Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • FSC Wealth Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $499K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on FSC Wealth Advisors's 13F filing for Q4 2022, filed 17 Jan 2023.